HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Facet-joint injections for people with persistent non-specific low back pain (FIS): study protocol for a randomised controlled feasibility trial.

AbstractBACKGROUND:
The role of injections of therapeutic substances into the back as treatment for low back pain is unclear. Facet joint injections are widely used despite the absence of evidence of sustained benefit. We hypothesise that facet joint injections might facilitate engagement with physiotherapist-led, best usual care (a combined physical and psychological programme) and is a clinically and cost-effective treatment for people with suspected low back pain of facet joint origin.
METHODS/DESIGN:
We present here the protocol for a randomised controlled feasibility trial for a main trial to test the above hypotheses. Patients referred to secondary care with persistent non-specific low back pain will be screened and invited to take part in the study. Those who meet the eligibility criteria will be invited for a physiotherapy assessment to confirm trial eligibility and for baseline data collection. All participants (n = 150) will be offered the best usual care package with physical and psychological components. Those randomised into the intervention arm (n = 75) will, in addition, receive intra-articular facet joint injections with local anaesthetic and steroids. Primary outcome data will be collected using daily and then weekly text messaging service for a pain score on a 0-10 scale. Questionnaire follow-up will be at 3, 6, and 12 months. Evaluation of trial processes and health economic analyses, including a value of information analysis, will be undertaken. The process evaluation will be mixed methods and will include the views of all stakeholders.
DISCUSSION:
Whilst this trial is a feasibility study it is currently one of the largest trials in this area. The outcomes will provide some evidence on the use of facet joint injections for patients with clinically diagnosed facet joint pain.
TRIAL REGISTRATION:
EudraCT identifier 2014-000682-50, (registered on 12 February 14). ISRCTN registry number: ISRCTN93184143 DOI 10.1186/ISRCTN93184143 (registered on 27 February 2014).
AuthorsHarbinder Sandhu, David R Ellard, Felix Achana, James H L Antrobus, Shyam Balasubramanian, Sally Brown, Melinda Cairns, Frances Griffiths, Kirstie Haywood, Charles Hutchinson, Ranjit Lall, Stavros Petrou, Nigel Stallard, Colin Tysall, David A Walsh, Martin Underwood
JournalTrials (Trials) Vol. 16 Pg. 588 (Dec 24 2015) ISSN: 1745-6215 [Electronic] England
PMID26703477 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Adrenal Cortex Hormones
  • Analgesics
  • Anesthetics, Local
Topics
  • Adrenal Cortex Hormones (administration & dosage, adverse effects)
  • Analgesics (administration & dosage, adverse effects)
  • Anesthetics, Local (administration & dosage, adverse effects)
  • Clinical Protocols
  • Feasibility Studies
  • Humans
  • Injections, Intra-Articular
  • Low Back Pain (diagnosis, drug therapy, physiopathology)
  • Pain Measurement
  • Research Design
  • Surveys and Questionnaires
  • Time Factors
  • Treatment Outcome
  • United Kingdom
  • Zygapophyseal Joint (drug effects, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: